FindTrial
Sign In

Remdesevir and Hydroxychloroquine in moderate to severe Covid 19 patient.

Efficacy of Remdesevir and Hydroxychloroquine in moderate to severe COVID-19 patients admitted in the CCU of a tertiary care hospital in WestBengal,India.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/02/031430
Enrollment
50
Registered
2021-02-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Remdesevir: One group will receive Remdesevir 200 mg iv day 1 followed by 100 mg iv day 2-5 Intervention2: Hydroxychloroquine: Another group will receive Hydroxychloroquine 400 mg orall

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: COVID RTPCR POSITIVE CASES PNEUNONITIS AS EFIDENT FROM CXR, HRCT THORAX REQUIRING OXYGEN VIA NRBM OR HIGHER SUPPORT LIKE HFNO,NIV OR INVASIVE VENTILATION

Exclusion criteria

Exclusion criteria: H/O DRUG ALLERGY TO ANY OF THE STUDY DRUGS H/O ADVERSE DRUG REACTION TO ANY OF THE STUDY DRUGS ELEVATED LIVER ENZYMES H/O OCCULAR DISEASE H/O CARDIO VASCULAR CONDUCTION DISEASE

Design outcomes

Primary

MeasureTime frame
AFEBRILE FOR 3 DAYS OR MORE RR 24/MIN OR LESS SPO2 94% OR MORE IN ROOM AIR NO RESPIRATORY DISTRESS, COUGH ETCTimepoint: 4 weeks—

Secondary

MeasureTime frame
Morbidity if any Mortality if any Adverse reactionsTimepoint: 0-30DAYS—

Countries

India

Contacts

Public ContactASIM KUMAR KUNDU

MEDICAL COLLEGE KOLKATA

drslahiri11@gmail.com9830217131

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026